PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.

doi:10.1158/2159-8290.CD-21-1671

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.

Cancer discovery - 2 Sept 2022

Patel Amish J, Warda Sarah, Maag Jesper L V, Misra Rohan, Miranda-Román Miguel A, Pachai Mohini R, Lee Cindy J, Li Dan, Wang Naitao, Bayshtok Gabriella, Fishinevich Eve, Meng Yinuo, Wong Elissa W P, Yan Juan, Giff Emily, Pappalardi Melissa B, McCabe Michael T, Fletcher Jonathan A, Rudin Charles M, Chandarlapaty Sarat, Scandura Joseph M, Koche Richard P, Glass Jacob L, Antonescu Cristina R, Zheng Deyou, Chen Yu, Chi Ping

Abstract excerpt

Polycomb repressive complex 2 (PRC2) has oncogenic and tumor-suppressive roles in cancer. There is clinical success of targeting this complex in PRC2-dependent cancers, but an unmet therapeutic need exists in PRC2-loss cancer. PRC2-inactivating mutations are a hallmark feature of high-grade malignant peripheral nerve sheath tumor (MPNST), an aggressive sarcoma with poor prognosis and no effective targeted...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Carcinogenesis

Share to Glioma Diagnosis and Treatment

Share to Mutation

Share to Neoplasms

Share to Neurofibromatosis and Schwannoma Cases

Share to Polycomb Repressive Complex 2

Share to Retroelements

Source

Open in PubMed Open full text

Identifiers

PMID: 35789380
DOI: 10.1158/2159-8290.CD-21-1671
PMCID: PMC9437570

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.PMID 35789380Read ↗

PRC2 Inactivating Mutations in Cancer are Synthetic Lethal with DNMT1 Targeted Therapy via Enhanced Viral MimicrySemantic proximity Read ↗

Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert tumor microenvironment and confers resistance to immunotherapySemantic proximity Read ↗

Epigenomic Reordering Induced by Polycomb Loss Drives Oncogenesis but Leads to Therapeutic Vulnerabilities in Malignant Peripheral Nerve Sheath TumorsSemantic proximity Read ↗

PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors.Semantic proximity Read ↗

PRC2 Restricts Malignant Peripheral Nerve Sheath Tumorigenesis in a Genetically Engineered Mouse Model of MPNSTSemantic proximity Read ↗

H3K27me3 expression and methylation status in histological variants of malignant peripheral nerve sheath tumoursSemantic proximity Read ↗

Genomic patterns of malignant peripheral nerve sheath tumour (MPNST) evolution correlate with clinical outcome and are detectable in cell-free DNASemantic proximity Read ↗

Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNASemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.